Search for "sulfonamide" in Full Text gives 130 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2016, 12, 22–28, doi:10.3762/bjoc.12.4
Graphical Abstract
Figure 1: Examples of valuable 1,2-oxyamino-containing molecules.
Scheme 1: Strategies for intermolecular olefin oxyamination.
Scheme 2: Examples of carboxylic acids in the olefin oxyamination reaction. Reaction conditions: 1 (1.2 mmol,...
Scheme 3: Examples of O-benzoylhydroxylamines in the olefin oxyamination reaction. Reaction conditions: 1a (1...
Beilstein J. Org. Chem. 2015, 11, 2223–2241, doi:10.3762/bjoc.11.241
Graphical Abstract
Figure 1: Some ruthenium catalysts for metathesis reactions.
Scheme 1: Decomposition of methylidenes 1 and 2.
Scheme 2: Deactivation of G-HII in the presence of ethylene.
Scheme 3: Reaction between GI/GII and n-BuNH2.
Scheme 4: Reaction of GII with amines a–d.
Scheme 5: Amine-induced decomposition of GII methylidene 2.
Scheme 6: Amine-induced decomposition of GII in RCM conditions.
Scheme 7: Deactivation of methylidene 2 in the presence of pyridine.
Scheme 8: Reaction of G-HII with various amines.
Scheme 9: Formation of olefin 22 from styrene.
Scheme 10: Hypothetic deactivation pathway of G-HII.
Scheme 11: RCM of dienic pyridinium salts.
Scheme 12: Synthesis of polycyclic scaffolds using RCM.
Scheme 13: Enyne ring-closing metathesis.
Scheme 14: Synthesis of (R)-(+)-muscopyridine using a RCM strategy.
Scheme 15: Synthesis of a tris-pyrrole macrocycle.
Scheme 16: Synthesis of a bicyclic imidazole.
Scheme 17: RCM using Schrock’s catalyst 44.
Scheme 18: Synthesis of 1,6-pyrido-diazocine 46 by using a RCM.
Scheme 19: Synthesis of fused pyrimido-azepines through RCM.
Scheme 20: RCM involving alkenes containing various N-heteroaromatics.
Scheme 21: Synthesis of dihydroisoquinoline using a RCM.
Scheme 22: Formation of tricyclic compound 59.
Scheme 23: RCM in the synthesis of normuscopyridine.
Scheme 24: Synthesis of macrocycle 64.
Scheme 25: Synthesis of macrocycles possessing an imidazole group.
Scheme 26: Retrosynthesis of an analogue of erythromycin.
Scheme 27: Retrosynthesis of haminol A.
Scheme 28: CM involving 3-vinylpyridine 70 with 71 and vinylpyridine 70 with 73.
Scheme 29: Revised retrosynthesis of haminol A.
Scheme 30: CM between 78 and crotonaldehyde.
Scheme 31: Hypothesized deactivation pathway.
Scheme 32: CM involving an allyl sulfide containing a quinoline.
Scheme 33: CM involving allylic sulfide possessing a quinoxaline or a phenanthroline.
Scheme 34: CM between an acrylate and a 2-methoxy-5-bromo pyridine.
Scheme 35: Successful CM of an alkene containing a 2-chloropyridine.
Scheme 36: Variation of the substituent on the pyridine ring.
Scheme 37: CM involving alkenes containing a variety of N-heteroaromatics.
Beilstein J. Org. Chem. 2015, 11, 2209–2222, doi:10.3762/bjoc.11.240
Graphical Abstract
Scheme 1: Copper-catalyzed C–H amidation of tertiary amines.
Scheme 2: Copper-catalyzed C–H amidation and sulfonamidation of tertiary amines.
Scheme 3: Copper-catalyzed sulfonamidation of allylic C–H bonds.
Scheme 4: Copper-catalyzed sulfonamidation of benzylic C–H bonds.
Scheme 5: Copper-catalyzed sulfonamidation of C–H bonds adjacent to oxygen.
Scheme 6: Copper-catalyzed amidation and sulfonamidation of inactivated alkyl C–H bonds.
Scheme 7: Copper-catalyzed amidation and sulfonamidation of inactivated alkanes.
Scheme 8: Copper-catalyzed intramolecular C–H amidation for lactam synthesis.
Scheme 9: Copper-catalyzed intramolecular C–H amidation for lactam synthesis.
Scheme 10: Copper-catalyzed amidation/sulfonamidation of aryl C–H bonds.
Scheme 11: C–H amidation of pyridinylbenzenes and indoles.
Scheme 12: Mechanism of the Cu-catalyzed C2-amidation of indoles.
Scheme 13: Copper-catalyzed, 2-phenyl oxazole-assisted C–H amidation of benzamides.
Scheme 14: DG-assisted amidation/imidation of indole and benzene C–H bonds.
Scheme 15: Copper-catalyzed C–H amination/amidation of quinoline N-oxides.
Scheme 16: Copper-catalyzed aldehyde formyl C–H amidation.
Scheme 17: Copper-catalyzed formamide C–H amidation.
Scheme 18: Copper-catalyzed sulfonamidation of vinyl C–H bonds.
Scheme 19: CuCl2-catalyzed amidation/sulfonamidation of alkynyl C–H bonds.
Scheme 20: Cu(OH)2-catalyzed amidation/sulfonamidation of alkynyl C–H bonds.
Scheme 21: Sulfonamidation-based cascade reaction for the synthesis of tetrahydrotriazines.
Scheme 22: Copper-catalyzed cascade reaction for the synthesis of quinazolinones.
Scheme 23: Copper-catalyzed cascade reactions for the synthesis of fused quinazolinones.
Scheme 24: Copper-catalyzed synthesis of quinazolinones via methyl C–H bond amidation.
Scheme 25: Dicumyl peroxide-based cascade synthesis of quinazolinones.
Scheme 26: Copper-catalyzed cascade reactions for the synthesis of indolinones.
Beilstein J. Org. Chem. 2015, 11, 1886–1892, doi:10.3762/bjoc.11.203
Graphical Abstract
Figure 1: Catalysts 1–4 tested for the metathesis of profluorescent substrates.
Scheme 1: Two profluorescent substrates yielding fluorescent products upon ring-closing metathesis.
Scheme 2: Synthesis of the two profluorescent substrates amenable to ring-closing metathesis.
Figure 2: Fluorescence evolution resulting from closing metathesis of umbelliferone precursor 8 (λexcitation ...
Figure 3: Fluorescence evolution resulting from closing metathesis of fluorescence–quencher substrate 5 (λexc...
Figure 4: Comparison of kinetics measured by HPLC a) and by a plate reader b) for the ring-closing metathesis...
Beilstein J. Org. Chem. 2015, 11, 1833–1864, doi:10.3762/bjoc.11.199
Graphical Abstract
Figure 1: Ruthenium alkylidene catalysts used in RRM processes.
Figure 2: General representation of various RRM processes.
Figure 3: A general mechanism for RRM process.
Scheme 1: RRM of cyclopropene systems.
Scheme 2: RRM of cyclopropene with catalyst 2. (i) catalyst 2 (2.5 mol %), ethylene (24, 1 atm), (ii) toluene...
Scheme 3: RRM of various cyclopropene derivatives with catalyst 2. (i) catalyst 2 (2.5 mol %), CH2Cl2 (c = 0....
Scheme 4: RRM of substituted cyclopropene system with catalyst 2.
Scheme 5: RRM of cyclobutene system with catalyst 2.
Scheme 6: RRM approach to various bicyclic compounds.
Scheme 7: RRM approach to erythrina alkaloid framework.
Scheme 8: ROM–RCM sequence to lactone derivatives.
Scheme 9: RRM protocol towards the synthesis of lactone derivative 58.
Scheme 10: RRM protocol towards the asymmetric synthesis of asteriscunolide D (61).
Scheme 11: RRM strategy towards the synthesis of various macrolide rings.
Scheme 12: RRM protocol to dipiperidine system.
Scheme 13: RRM of cyclopentene system to generate the cyclohexene systems.
Scheme 14: RRM of cyclopentene system 74.
Scheme 15: RRM approach to compound 79.
Scheme 16: RRM approach to spirocycles.
Scheme 17: RRM approach to bicyclic dihydropyrans.
Scheme 18: RCM–ROM–RCM cascade using non strained alkenyl heterocycles.
Scheme 19: First ROM–RCM–ROM–RCM cascade for the synthesis of trisaccharide 97.
Scheme 20: RRM of cyclohexene system.
Scheme 21: RRM approach to tricyclic spirosystem.
Scheme 22: RRM approach to bicyclic building block 108a.
Scheme 23: ROM–RCM protocol for the synthesis of the bicyclo[3.3.0]octene system.
Scheme 24: RRM protocol to bicyclic enone.
Scheme 25: RRM protocol toward the synthesis of the tricyclic system 118.
Scheme 26: RRM approach toward the synthesis of the tricyclic enones 122a and 122b.
Scheme 27: Synthesis of tricyclic and tetracyclic systems via RRM protocol.
Scheme 28: RRM protocol towards the synthesis of tetracyclic systems.
Scheme 29: RRM of the propargylamino[2.2.1] system.
Scheme 30: RRM of highly decorated bicyclo[2.2.1] systems.
Scheme 31: RRM protocol towards fused tricyclic compounds.
Scheme 32: RRM protocol to functionalized tricyclic systems.
Scheme 33: RRM approach to functionalized polycyclic systems.
Scheme 34: Sequential RRM approach to functionalized tricyclic ring system 166.
Scheme 35: RRM protocol to functionalized CDE tricyclic ring system of schintrilactones A and B.
Scheme 36: Sequential RRM approach to 7/5 fused bicyclic systems.
Scheme 37: Sequential ROM-RCM protocol for the synthesis of bicyclic sugar derivatives.
Scheme 38: ROM–RCM sequence of the norbornene derivatives 186 and 187.
Scheme 39: RRM approach toward highly functionalized bridge tricyclic system.
Scheme 40: RRM approach toward highly functionalized tricyclic systems.
Scheme 41: Synthesis of hexacyclic compound 203 by RRM approach.
Scheme 42: RRM approach toward C3-symmetric chiral trimethylsumanene 209.
Scheme 43: Triquinane synthesis via IMDA reaction and RRM protocol.
Scheme 44: RRM approach to polycyclic compounds.
Scheme 45: RRM strategy toward cis-fused bicyclo[3.3.0]carbocycles.
Scheme 46: RRM protocol towards the synthesis of bicyclic lactone 230.
Scheme 47: RRM approach to spiro heterocyclic compounds.
Scheme 48: RRM approach to spiro heterocyclic compounds.
Scheme 49: RRM approach to regioselective pyrrolizidine system 240.
Scheme 50: RRM approach to functionalized bicyclic derivatives.
Scheme 51: RRM approach to tricyclic derivatives 249 and 250.
Scheme 52: RRM approach to perhydroindoline derivative and spiro system.
Scheme 53: RRM approach to bicyclic pyran derivatives.
Scheme 54: RRM of various functionalized oxanorbornene systems.
Scheme 55: RRM to assemble the spiro fused-furanone core unit. (i) 129, benzene, 55 °C, 3 days; (ii) Ph3P=CH2B...
Scheme 56: RRM protocol to norbornenyl sultam systems.
Scheme 57: Ugi-RRM protocol for the synthesis of 2-aza-7-oxabicyclo system.
Scheme 58: Synthesis of spiroketal systems via RRM protocol.
Scheme 59: RRM approach to cis-fused heterotricyclic system.
Scheme 60: RRM protocol to functionalized bicyclic systems.
Scheme 61: ROM/RCM/CM cascade to generate bicyclic scaffolds.
Scheme 62: RCM of ROM/CM product.
Scheme 63: RRM protocol to bicyclic isoxazolidine ring system.
Scheme 64: RRM approach toward the total synthesis of (±)-8-epihalosaline (300).
Scheme 65: Sequential RRM approach to decalin 304 and 7/6 fused 305 systems.
Scheme 66: RRM protocol to various fused carbocyclic derivatives.
Scheme 67: RRM to cis-hydrindenol derivatives.
Scheme 68: RRM protocol towards the cis-hydrindenol derivatives.
Scheme 69: RRM approach toward the synthesis of diversed polycyclic lactams.
Scheme 70: RRM approach towards synthesis of hexacyclic compound 324.
Scheme 71: RRM protocol to generate luciduline precursor 327 with catalyst 2.
Scheme 72: RRM protocol to key building block 330.
Scheme 73: RRM approach towards the synthesis of key intermediate 335.
Scheme 74: RRM protocol to highly functionalized spiro-pyran system 339.
Scheme 75: RRM to various bicyclic polyether derivatives.
Beilstein J. Org. Chem. 2015, 11, 1649–1655, doi:10.3762/bjoc.11.181
Graphical Abstract
Figure 1: (a) Radical reactions of ene-sulfonamides give diverse isolated products; (b) these products are of...
Figure 2: Isolation of stable imines strengthens the case for sulfonyl radical elimination.
Scheme 1: Cyclizations of N-sulfonylindole 3 occur with retention or elimination of the sulfonyl group depend...
Scheme 2: Aryl radical cyclization to N-sulfonylindoles.
Figure 3: Mechanistic aspects of cyclizations shown in Scheme 2; (a) mechanism for formation of 7; (b) possible reaso...
Figure 4: Substrate design by swapping radical precursor and acceptor.
Scheme 3: Synthesis and cyclization of precursors 22–24.
Figure 5: ORTEP representation of the crystal structure of 27.
Figure 6: Proposed hydration/retro-Claisen path to formamides.
Beilstein J. Org. Chem. 2015, 11, 1274–1331, doi:10.3762/bjoc.11.142
Graphical Abstract
Figure 1: General representation of cyclophanes.
Figure 2: cyclophanes one or more with heteroatom.
Figure 3: Metathesis catalysts 12–17 and C–C coupling catalyst 18.
Figure 4: Natural products containing the cyclophane skeleton.
Figure 5: Turriane family of natural products.
Scheme 1: Synthesis of [3]ferrocenophanes through Mannich reaction. Reagents and conditions: (i) excess HNMe2...
Scheme 2: Synthesis of cyclophanes through Michael addition. Reagents and conditions: (i) xylylene dibromide,...
Scheme 3: Synthesis of normuscopyridine analogue 37 through an oxymercuration–oxidation strategy. Reagents an...
Scheme 4: Synthesis of tribenzocyclotriyne 39 through Castro–Stephens coupling reaction. Reagents and conditi...
Scheme 5: Synthesis of cyclophane 43 through Glaser–Eglinton coupling. Reagents and conditions: (i) 9,10-bis(...
Scheme 6: Synthesis of the macrocyclic C-glycosyl cyclophane through Glaser coupling. Reagents and conditions...
Scheme 7: Synthesis of cyclophane-containing complex 49 through Glaser–Eglinton coupling reaction. Reagents a...
Scheme 8: Synthesis of cyclophane 53 through Glaser–Eglinton coupling. Reagents and conditions: (i) K2CO3, ac...
Figure 6: Cyclophanes 54–56 that have been synthesized through Glaser–Eglinton coupling.
Figure 7: Synthesis of tetrasubstituted [2.2]paracyclophane 57 and chiral cyclophyne 58 through Eglinton coup...
Scheme 9: Synthesis of cyclophane through Glaser–Hay coupling reaction. Reagents and conditions: (i) CuCl2 (1...
Scheme 10: Synthesis of seco-C/D ring analogs of ergot alkaloids through intramolecular Heck reaction. Reagent...
Scheme 11: Synthesis of muscopyridine 73 via Kumada coupling. Reagents and conditions: (i) 72, THF, ether, 20 ...
Scheme 12: Synthesis of the cyclophane 79 via McMurry coupling. Reagents and conditions: (i) 75, decaline, ref...
Scheme 13: Synthesis of stilbenophane 81 via McMurry coupling. Reagents and conditions: (i) TiCl4, Zn, pyridin...
Scheme 14: Synthesis of stilbenophane 85 via McMurry coupling. Reagents and conditions: (i) NBS (2 equiv), ben...
Figure 8: List of cyclophanes prepared via McMurry coupling reaction as a key step.
Scheme 15: Synthesis of paracyclophane by cross coupling involving Pd(0) catalyst. Reagents and conditions: (i...
Scheme 16: Synthesis of the cyclophane 112 via the pinacol coupling and 113 by RCM. Reagents and conditions: (...
Scheme 17: Synthesis of cyclophane derivatives 122a–c via Sonogoshira coupling. Reagents and conditions: (i) C...
Scheme 18: Synthesis of cyclophane 130 via Suzuki–Miyaura reaction as a key step. Reagents and conditions: (i)...
Scheme 19: Synthesis of the mycocyclosin via Suzuki–Miyaura cross coupling. Reagents and conditions: (i) benzy...
Scheme 20: Synthesis of cyclophanes via Wurtz coupling reaction Reagents and conditions: (i) PhLi, Et2O, C6H6,...
Scheme 21: Synthesis of non-natural glycophanes using alkyne metathesis. Reagents and conditions: (i) G-I (12)...
Figure 9: Synthesis of cyclophanes via ring-closing alkyne metathesis.
Scheme 22: Synthesis of crownophanes by cross-enyne metathesis. Reagents and conditions: (i) G-II (13), 5 mol ...
Scheme 23: Synthesis of (−)-cylindrocyclophanes A (156) and (−)-cylindrocyclophanes F (155). Reagents and cond...
Scheme 24: Synthesis of cyclophane 159 derivatives via SM cross-coupling and RCM. Reagents and conditions: (i)...
Scheme 25: Sexithiophene synthesis via cross metathesis. Reagents and conditions: (i) 161, Pd(PPh3)4, K2CO3, T...
Scheme 26: Synthesis of pyrrole-based cyclophane using enyne metathesis. Reagents and conditions: (i) Se, chlo...
Scheme 27: Synthesis of macrocyclic derivatives by RCM. Reagents and conditions: (i) G-I/G-II, CH2Cl2, 0.005 M...
Scheme 28: Synthesis of enantiopure β-lactam-based dienyl bis(dihydrofuran) 179. Reagents and conditions: (i) ...
Scheme 29: Synthesis of a [1.1.6]metaparacyclophane derivative 183 via SM cross coupling. Reagents and conditi...
Scheme 30: Synthesis of a [1.1.6]metaparacyclophane derivative 190 via SM cross coupling. Reagents and conditi...
Scheme 31: Template-promoted synthesis of cyclophanes involving RCM. Reagents and conditions: (i) acenaphthene...
Scheme 32: Synthesis of [3.4]cyclophane derivatives 200 via SM cross coupling and RCM. Reagents and conditions...
Figure 10: Examples for cyclophanes synthesized by RCM.
Scheme 33: Synthesis of the longithorone C framework assisted by fluorinated auxiliaries. Reagents and conditi...
Scheme 34: Synthesis of the longithorone framework via RCM. Reagents and conditions: (i) 213, NaH, THF, rt, 10...
Scheme 35: Synthesis of floresolide B via RCM as a key step. Reagents and conditions: (i) G-II (13, 0.1 equiv)...
Scheme 36: Synthesis of normuscopyridine (223) by the RCM strategy. Reagents and condition: (i) Mg, THF, hexen...
Scheme 37: Synthesis of muscopyridine (73) via RCM. Reagents and conditions: (i) 225, NaH, THF, 0 °C to rt, 1....
Scheme 38: Synthesis of muscopyridine (73) via RCM strategy. Reagents and conditions: (i) NaH, n-BuLi, 5-bromo...
Scheme 39: Synthesis of pyridinophane derivatives 223 and 245. Reagents and conditions: (i) PhSO2Na, TBAB, CH3...
Scheme 40: Synthesis of metacyclophane derivatives 251 and 253. Reagents and conditions: (i) 240, NaH, THF, rt...
Scheme 41: Synthesis of normuscopyridine and its higher analogues. Reagents and conditions: (i) alkenyl bromid...
Scheme 42: Synthesis of fluorinated ferrocenophane 263 via a [2 + 2] cycloaddition. Reagents and conditions: (...
Scheme 43: Synthesis of [2.n]metacyclophanes 270 via a [2 + 2] cycloaddition. Reagents and conditions: (i) Ac2...
Scheme 44: Synthesis of metacyclophane 273 by a [2 + 2 + 2] co-trimerization. Reagents and conditions: (i) [Rh...
Scheme 45: Synthesis of paracyclophane 276 via a [2 + 2 + 2] cycloaddition reaction. Reagents and conditions: ...
Scheme 46: Synthesis of cyclophane 278 via a [2 + 2 + 2] cycloaddition reaction. Reagents and conditions: (i) ...
Scheme 47: Synthesis of cyclophane 280 via a [2 + 2 + 2] cycloaddition. Reagents and conditions: (i) [(Rh(cod)(...
Scheme 48: Synthesis of taxane framework by a [2 + 2 + 2] cycloaddition. Reagents and conditions: (i) Cp(CO)2 ...
Scheme 49: Synthesis of cyclophane 284 and 285 via a [2 + 2 + 2] cycloaddition reaction. Reagents and conditio...
Scheme 50: Synthesis of pyridinophanes 293a,b and 294a,b via a [2 + 2 + 2] cycloaddition. Reagents and conditi...
Scheme 51: Synthesis of pyridinophanes 296 and 297 via a [2 + 2 + 2] cycloaddition. Reagents and conditions: (...
Scheme 52: Synthesis of triazolophane by a 1,3-dipolar cycloaddition. Reagents and conditions: (i) propargyl b...
Scheme 53: Synthesis of glycotriazolophane 309 by a click reaction. Reagents and conditions: (i) LiOH, H2O, Me...
Figure 11: Cyclophanes 310 and 311 prepared via click chemistry.
Scheme 54: Synthesis of cyclophane via the Dötz benzannulation. Reagents and conditions: (i) THF, 100 °C, 12 h...
Scheme 55: Synthesis of [6,6]metacyclophane by a Dötz benzannulation. Reagents and conditions: (i) THF, 100 °C...
Scheme 56: Synthesis of cyclophanes by a Dötz benzannulation. Reagents and conditions: (i) THF, 65 °C, 3 h; (i...
Scheme 57: Synthesis of muscopyridine (73) via an intramolecular DA reaction of ketene. Reagents and condition...
Scheme 58: Synthesis of bis[10]paracyclophane 336 via Diels–Alder reaction. Reagents and conditions: (i) DMAD,...
Scheme 59: Synthesis of [8]paracyclophane via DA reaction. Reagents and conditions: (i) maleic anhydride, 3–5 ...
Scheme 60: Biomimetic synthesis of (−)-longithorone A. Reagents and conditions: (i) Me2AlCl, CH2Cl2, −20 °C, 7...
Scheme 61: Synthesis of sporolide B (349) via a [4 + 2] cycloaddition reaction. Reagents and conditions: (i) P...
Scheme 62: Synthesis of the framework of (+)-cavicularin (352) via a [4 + 2] cycloaddition. Reagents and condi...
Scheme 63: Synthesis of oxazole-containing cyclophane 354 via Beckmann rearrangement. Reagents and conditions:...
Scheme 64: Synthesis of cyclophanes 360a–c via benzidine rearrangement. Reagents and conditions: (i) 356a–d, K2...
Scheme 65: Synthesis of cyclophanes 365a–c via benzidine rearrangement. Reagents and conditions: (i) BocNHNH2,...
Scheme 66: Synthesis of metacyclophane 367 via Ciamician–Dennstedt rearrangement. Reagents and conditions: (i)...
Scheme 67: Synthesis of cyclophane by tandem Claisen rearrangement and RCM as key steps. Reagents and conditio...
Scheme 68: Synthesis of cyclophane derivative 380. Reagents and conditions: (i) K2CO3, CH3CN, allyl bromide, r...
Scheme 69: Synthesis of metacyclophane via Cope rearrangement. Reagents and conditions: (i) MeOH, NaBH4, rt, 1...
Scheme 70: Synthesis of cyclopropanophane via Favorskii rearrangement. Reagents and conditions: (i) Br2, CH2Cl2...
Scheme 71: Cyclophane 389 synthesis via photo-Fries rearrangement. Reagents and conditions: (i) DMAP, EDCl/CHCl...
Scheme 72: Synthesis of normuscopyridine (223) via Schmidt rearrangement. Reagents and conditions: (i) ethyl s...
Scheme 73: Synthesis of crownophanes by tandem Claisen rearrangement. Reagents and conditions: (i) diamine, Et3...
Scheme 74: Attempted synthesis of cyclophanes via tandem Claisen rearrangement and RCM. Reagents and condition...
Scheme 75: Synthesis of muscopyridine via alkylation with 2,6-dimethylpyridine anion. Reagents and conditions:...
Scheme 76: Synthesis of cyclophane via Friedel–Craft acylation. Reagents and conditions: (i) CS2, AlCl3, 7 d, ...
Scheme 77: Pyridinophane 418 synthesis via Friedel–Craft acylation. Reagents and conditions: (i) 416, AlCl3, CH...
Scheme 78: Cyclophane synthesis involving the Kotha–Schölkopf reagent 421. Reagents and conditions: (i) NBS, A...
Scheme 79: Cyclophane synthesis involving the Kotha–Schölkopf reagent 421. Reagents and conditions: (i) BEMP, ...
Scheme 80: Cyclophane synthesis by coupling with TosMIC. Reagents and conditions: (i) (a) ClCH2OCH3, TiCl4, CS2...
Scheme 81: Synthesis of diaza[32]cyclophanes and triaza[33]cyclophanes. Reagents and conditions: (i) DMF, NaH,...
Scheme 82: Synthesis of cyclophane 439 via acyloin condensation. Reagents and conditions: (i) Na, xylene, 75%;...
Scheme 83: Synthesis of multibridged binuclear cyclophane 442 by aldol condensation. Reagents and conditions: ...
Scheme 84: Synthesis of various macrolactones. Reagents and conditions: (i) iPr2EtN, DMF, 77–83%; (ii) TBDMSCl...
Scheme 85: Synthesis of muscone and muscopyridine via Yamaguchi esterification. Reagents and conditions: (i) 4...
Scheme 86: Synthesis of [5]metacyclophane via a double elimination reaction. Reagents and conditions: (i) LiBr...
Figure 12: Cyclophanes 466–472 synthesized via Hofmann elimination.
Scheme 87: Synthesis of cryptophane via Baylis–Hillman reaction. Reagents and conditions: (i) methyl acrylate,...
Scheme 88: Synthesis of cyclophane 479 via double Chichibabin reaction. Reagents and conditions: (i) excess 478...
Scheme 89: Synthesis of cyclophane 483 via double Chichibabin reaction. Reagents and conditions: (i) 481, OH−;...
Scheme 90: Synthesis of cyclopeptide via an intramolecular SNAr reaction. Reagents and conditions: (i) TBAF, T...
Scheme 91: Synthesis of muscopyridine (73) via C-zip ring enlargement reaction. Reagents and conditions: (i) H...
Figure 13: Mechanism of the formation of compound 494.
Scheme 92: Synthesis of indolophanetetraynes 501a,b using the Nicholas reaction as a key step. Reagents and co...
Scheme 93: Synthesis of cyclophane via radical cyclization. Reagents and conditions: (i) cyclododecanone, phen...
Scheme 94: Synthesis of (−)-cylindrocyclophanes A (156) and (−)-cylindrocyclophanes F (155). Reagents and cond...
Scheme 95: Cyclophane synthesis via Wittig reaction. Reagents and conditions: (i) LiOEt (2.1 equiv), THF, −78 ...
Figure 14: Representative examples of cyclophanes synthesized via Wittig reaction.
Scheme 96: Synthesis of the [6]paracyclophane via isomerization of Dewar benzene. Reagents and conditions: (i)...
Beilstein J. Org. Chem. 2015, 11, 1226–1234, doi:10.3762/bjoc.11.136
Graphical Abstract
Scheme 1: Preparation of the chloroamides.
Scheme 2: First experiments for the intermolecular radical addition.
Scheme 3: Reaction of sterically hindered N-chlorosulfonamides.
Scheme 4: Proposed mechanism of the chlorination.
Scheme 5: Ring opening in the case of cationic or radical intermediates.
Scheme 6: Addition to unsaturated alcohols prone to halocyclization.
Beilstein J. Org. Chem. 2015, 11, 1129–1135, doi:10.3762/bjoc.11.127
Graphical Abstract
Figure 1: Function and inhibition of hCAII. a) hCAII (pdb: 2vva [7]) catalyzes the hydration of carbon dioxide t...
Scheme 1: Synthesis and characterization of azobenzene-containing aryl sulfonamides by different strategies. ...
Figure 2: Crystal structures for compounds 1a–i (co-solvents and/or multiple molecules in the asymmetric cell...
Figure 3: Crystal structure of hCAII bound to 1d (pdb: 5byi). a) The terminal amine of 1d is solvent-exposed,...
Figure 4: Inhibition of hCAII by electronically different azobenzene sulfonamides and AAZ. a) Endpoint measur...
Beilstein J. Org. Chem. 2015, 11, 596–603, doi:10.3762/bjoc.11.66
Graphical Abstract
Figure 1: Some indolizidine alkaloids.
Figure 2: Approaches to racemic tashiromine and epitashiromine.
Figure 3: Synthetic routes to (+)-tashiromine and (+)-epitashiromine.
Figure 4: Synthetic routes to (−)-tashiromine and (−)-epitashiromine.
Figure 5: Oxidative functionalizations of cyclic β-amino acids.
Scheme 1: Retrosynthesis of tashiromine and epitashiromine.
Scheme 2: Synthesis of (±)-tashiromine ((±)-6).
Scheme 3: Synthesis of (±)-epitashiromine ((±)-10).
Beilstein J. Org. Chem. 2015, 11, 416–424, doi:10.3762/bjoc.11.47
Graphical Abstract
Figure 1: Selected structures of fused quinazolinones.
Scheme 1: The intramolecular alkyne hydroamination of alkynes.
Scheme 2: A plausible mechanism.
Beilstein J. Org. Chem. 2015, 11, 249–264, doi:10.3762/bjoc.11.28
Graphical Abstract
Figure 1: Structure of 4-hydroxybenzyl alcohol (HBA, 1).
Figure 2: Structure–activity relationship of curcumin analogs.
Scheme 1: Synthesis of curcumin (3). Reagents and conditions: (a) vanillin, 1,2,3,4-tetrahydroquinoline, HOAc...
Figure 3: Backbone and substitution of monocarbonyl analogs of curcumin (MACs) showing their structural diver...
Scheme 2: Exemplary synthesis of MAC representatives. Reagents and conditions: (a) 40% KOH, EtOH, 5 °C; stirr...
Scheme 3: Synthesis of ellagic acid (7). Reagents and conditions: (a) H2SO4, CH3OH; (b) (1) o-chloranil, Et2O...
Figure 4: Structure of resveratrol and its analogs.
Scheme 4: Synthesis of quinolone-substituted phenol 20. Reagents and conditions: (a) Ac2O, 2-hydroxybenzaldeh...
Scheme 5: Synthesis of quinolone-substituted phenol 23. Reagents and conditions: (a) Ac2O, 2-hydroxybenzaldeh...
Figure 5: Design of 4-amino-2-sulfanylphenol derivatives and their structure–activity relationship.
Scheme 6: Synthesis of 4-amino-2-sulfanylphenol derivatives. Reagents and conditions: (a) R1SO2Cl, pyridine, ...
Figure 6: Structures of two series of natural-like acylphloroglucinols.
Scheme 7: Synthesis of acylphloroglucinol derivatives 35–41. Reagents and conditions: (a) acyl chloride, AlCl3...
Scheme 8: Synthesis of acylphloroglucinol derivatives 43–51. Reagents and conditions: (a) isoprene, Amberlyst...
Figure 7: Analogs of (−)-EGCG for the prevention of oxidation and improvement of the bioavailability of the c...
Scheme 9: Synthesis of xanthohumol 58. Reagents and conditions: (a) MOMCl, diisopropylethylamine, CH2Cl2; (b)...
Scheme 10: Synthesis of genistein 60. Reagents and conditions: (a) 4-hydroxyphenylacetonitrile, anhydrous HCl,...
Scheme 11: Synthesis of fisetin (67) and quercetin (68). Reagents and conditions: (a) 3,4-dimethoxybenzaldehyd...
Figure 8: Structure of (2S)-7,2’,4’-trihydroxy-5-methoxy-8-(dimethylallyl)flavanone (69).
Beilstein J. Org. Chem. 2014, 10, 2470–2479, doi:10.3762/bjoc.10.258
Graphical Abstract
Figure 1: Structure of the reporter molecule BPT (1).
Scheme 1: Synthesis of the azide-bearing 4-hydroxythiazole derivative 1.
Figure 2: Structure of the tested azide-modified standard fluorophores DNS (8) and NBD (9) and the bromine mo...
Figure 3: UV–vis spectra of 20 µM solutions of the azide modified fluorophores BPT (1), DNS (8), NBD (9) and ...
Figure 4: Normalized absorbance and fluorescence of BPT (1) in 20% THF/80% water (v/v), excitation at 374 nm.
Figure 5: Peak area of 100 pmol BPT (1), DNS (8), NBD (9) and BNS (6) measured with (A) C18-UPLC coupled to a...
Figure 6: Procedure of the model reaction between L-lysine and DDY (10) to form an imine (only one of two pos...
Figure 7: Mass spectra of labeled L-lysine/DDY (10)/fluorophore conjugates 11 (containing BPT), 12 (containin...
Figure 8: Fluorescent labeling of catalase treated with DDY (10) followed by CuAAC with all four reporter mol...
Beilstein J. Org. Chem. 2014, 10, 1848–1877, doi:10.3762/bjoc.10.195
Graphical Abstract
Figure 1: Examples of phosphonamide reagents used in stereoselective synthesis.
Figure 2: Natural products and bioactive molecules synthesized using phosphonamide-based chemistry (atoms, bo...
Scheme 1: Olefination with cyclic phosphonamide anions, mechanistic rationale, and selected examples 27a–d [18].
Scheme 2: Asymmetric olefination with chiral phosphonamide anions and selected examples 31a–d [1,22].
Scheme 3: Synthesis of α-substituted phosphonic acids 33a–e by asymmetric alkylation of chiral phosphonamide ...
Scheme 4: Asymmetric conjugate additions of C2-symmetric chiral phosphonamide anions to cyclic enones, lacton...
Scheme 5: Asymmetric conjugate additions of P-chiral phosphonamide anions generated from 40a and 44a to cycli...
Scheme 6: Asymmetric cyclopropanation with chiral chloroallyl phosphonamide 47, mechanistic rationale, and se...
Scheme 7: Asymmetric cyclopropanation with chiral chloromethyl phosphonamide 28d [59].
Scheme 8: Stereoselective synthesis of cis-aziridines 57 from chiral chloroallyl phosphonamide 47a [62].
Scheme 9: Synthesis of phosphonamides by (A) Arbuzov reaction, (B) condensation of diamines with phosphonic a...
Figure 3: Original and revised structure of polyoxin A (69) [24-26].
Scheme 10: Synthesis of (E)-polyoximic acid (9) [24-26].
Figure 4: Key assembly strategy of acetoxycrenulide (10) [41,42].
Scheme 11: Total synthesis of (+)-acetoxycrenulide (10) [41,42].
Scheme 12: Synthesis squalene synthase inhibitor 19 by asymmetric sulfuration (A) and asymmetric alkylation (B...
Figure 5: Key assembly strategy of fumonisin B2 (20) and its tricarballylic acid fragment 105 [45,46].
Scheme 13: Final steps of the total synthesis of fumonisin B2 (20) [45,46].
Figure 6: Selected examples of two subclasses of β-lactam antibiotics – carbapenems (111 and 112) and trinems...
Scheme 14: Synthesis of tricyclic β-lactam antibiotic 123 [97].
Scheme 15: Total synthesis of (−)-anthoplalone (8) [56].
Figure 7: Protein tyrosine phosphatase (PTP) inhibitors 130, 131 and model compounds 16, 132 and 133 [68].
Scheme 16: Synthesis of model PTP inhibitors 16a,b [68].
Scheme 17: Synthesis of aziridine hydroxamic acid 17 as MMP inhibitor [63].
Scheme 18: Synthesis of methyl jasmonate (11) [48].
Figure 8: Structures of nudiflosides A (137) and D (13) [49].
Scheme 19: Total synthesis of the pentasubstituted cyclopentane core 159 of nudiflosides A (151) and D (13) an...
Figure 9: L-glutamic acid (161) and constrained analogues [57,124].
Scheme 20: Stereoselective synthesis of DCG-IV (162) [57].
Scheme 21: Stereoselective synthesis of mGluR agonist 21 [124].
Figure 10: Key assembly strategy of berkelic acid (15) [43].
Scheme 22: Total synthesis of berkelic acid (15) [43].
Figure 11: Key assembly strategy of jerangolid A (22) and ambruticin S (14) [27,28].
Scheme 23: Final assembly steps in the total synthesis of jerangolid A [27].
Scheme 24: Key assembly steps in the total synthesis of ambruticin S (14) [28].
Figure 12: General steroid construction strategy based on conjugate addition of 212 to cyclopentenone 48, exem...
Scheme 25: Total synthesis of estrone (12) [44].
Beilstein J. Org. Chem. 2014, 10, 1166–1196, doi:10.3762/bjoc.10.117
Graphical Abstract
Scheme 1: Pioneer works of Atherton, Openshaw and Todd reporting on the synthesis of phosphoramidate starting...
Scheme 2: Mechanisms 1 (i) and 2 (ii) suggested by Atherton and Todd in 1945; adapted from [1].
Scheme 3: Two reaction pathways (i and ii) to produce chlorophosphate 2. Charge-transfer complex observed whe...
Scheme 4: Mechanism of the Atherton–Todd reaction with dimethylphosphite according to Roundhill et al. (adapt...
Scheme 5: Synthesis of dialkyl phosphate from dialkyl phosphite (i) and identification of chloro- and bromoph...
Scheme 6: Synthesis of chiral phosphoramidate with trichloromethylphosphonate as the suggested intermediate (...
Scheme 7: Selection of results that address the question of the stereochemistry of the AT reaction (adapted f...
Scheme 8: Synthesis of phenoxy spirophosphorane by the AT reaction (adapted from [34]).
Scheme 9: Suggested mechanism of the Atherton–Todd reaction, (i) and (ii) formation of chlorophosphate with a...
Scheme 10: AT reaction in biphasic conditions (adapted from [38]).
Scheme 11: AT reaction with iodoform as halide source (adapted from [37]).
Scheme 12: AT reaction with phenol at low temperature in the presence of DMAP (adapted from [40]).
Scheme 13: Synthesis of a triphosphate by the AT reaction starting with the preparation of chlorophosphate (ad...
Scheme 14: AT reaction with sulfonamide (adapted from [42]).
Scheme 15: Synthesis of a styrylphosphoramidate starting from the corresponding aniline (adapted from [43]).
Scheme 16: Use of hydrazine as nucleophile in AT reactions (adapted from [48]).
Scheme 17: AT reaction with phenol as a nucleophilic species; synthesis of dioleyl phosphate-substituted couma...
Scheme 18: Synthesis of β-alkynyl-enolphosphate from allenylketone with AT reaction (adapted from [58]).
Scheme 19: Synthesis of pseudohalide phosphate by using AT reaction (adapted from [67]).
Scheme 20: AT reaction with hydrospirophosphorane with insertion of CO2 in the product (adapted from [69]).
Scheme 21: AT reaction with diaryl phosphite (adapted from [70]).
Scheme 22: AT reaction with O-alkyl phosphonite (adapted from [71]).
Scheme 23: Use of phosphinous acid in AT reactions (adapted from [72]).
Scheme 24: AT reaction with secondary phosphinethiooxide (adapted from [76]).
Scheme 25: Use of H-phosphonothioate in the AT reaction (adapted from [78]).
Scheme 26: AT-like reaction with CuI as catalyst and without halide source (adapted from [80]).
Scheme 27: Reduction of phenols after activation as phosphate derivatives (adapted from [81] i ; [82], ii; and [83], iii).
Scheme 28: Synthesis of medium and large-sized nitrogen-containing heterocycles (adapted from [85]).
Scheme 29: Synthesis of arylstannane from aryl phosphate prepared by an AT reaction (adapted from [86]).
Scheme 30: Synthesis and use of aryl dialkyl phosphate for the synthesis of biaryl derivatives (adapted from [89])....
Scheme 31: Synthesis of aryl dialkyl phosphate by an AT reaction from phenol and subsequent rearrangement yiel...
Scheme 32: Selected chiral phosphoramidates used as organocatalyst; i) chiral phosphoramidate used in the pion...
Scheme 33: Determination of ee of H-phosphinate by the application of the AT reaction with a chiral amine (ada...
Scheme 34: Chemical structure of selected flame retardants synthesized by AT reactions; (BDE: polybrominated d...
Scheme 35: Transformation of DOPO (i) and synthesis of polyphosphonate (ii) by the AT reaction (adapted from [117] ...
Scheme 36: Synthesis of lipophosphite (bisoleyl phosphite) and cationic lipophosphoramidate with an AT reactio...
Scheme 37: Use of AT reactions to produce cationic lipids characterized by a trimethylphosphonium, trimethylar...
Scheme 38: Cationic lipid synthesized by the AT reaction illustrating the variation of the structure of the li...
Scheme 39: Helper lipids for nucleic acid delivery synthesized with the AT reaction (adapted from [130]).
Scheme 40: AT reaction used to produce red/ox-sensitive cationic lipids (adapted from [135]).
Scheme 41: Alkyne and azide-functionalized phosphoramidate synthesized by AT reactions,(i); illustration of so...
Scheme 42: Cationic lipids exhibiting bactericidal action – arrows indicate the bond formed by the AT reaction...
Scheme 43: β-Cyclodextrin-based lipophosphoramidates (adapted from [138]).
Scheme 44: Polyphosphate functionalized by an AT reaction (adapted from [139]).
Scheme 45: Synthesis of zwitterionic phosphocholine-bound chitosan (adapted from [142]).
Scheme 46: Synthesis of AZT-based prodrug via an AT reaction (adapted from [143]).
Beilstein J. Org. Chem. 2014, 10, 544–598, doi:10.3762/bjoc.10.50
Graphical Abstract
Scheme 1: The proposed mechanism of the Passerini reaction.
Scheme 2: The PADAM-strategy to α-hydroxy-β-amino amide derivatives 7. An additional oxidation provides α-ket...
Scheme 3: The general accepted Ugi-mechanism.
Scheme 4: Three commonly applied Ugi/cyclization approaches. a) UDC-process, b) UAC-sequence, c) UDAC-combina...
Scheme 5: Ugi reaction that involves the condensation of Armstrong’s convertible isocyanide.
Scheme 6: Mechanism of the U-4C-3CR towards bicyclic β-lactams.
Scheme 7: The Ugi 4C-3CR towards oxabicyclo β-lactams.
Scheme 8: Ugi MCR between an enantiopure monoterpene based β-amino acid, aldehyde and isocyanide resulting in...
Scheme 9: General MCR for β-lactams in water.
Scheme 10: a) Ugi reaction for β-lactam-linked peptidomimetics. b) Varying the β-amino acid resulted in β-lact...
Scheme 11: Ugi-4CR followed by a Pd-catalyzed Sn2 cyclization.
Scheme 12: Ugi-3CR of dipeptide mimics from 2-substituted pyrrolines.
Scheme 13: Joullié–Ugi reaction towards 2,5-disubstituted pyrrolidines.
Scheme 14: Further elaboration of the Ugi-scaffold towards bicyclic systems.
Scheme 15: Dihydroxyproline derivatives from an Ugi reaction.
Scheme 16: Diastereoselective Ugi reaction described by Banfi and co-workers.
Scheme 17: Similar Ugi reaction as in Scheme 16 but with different acids and two chiral isocyanides.
Scheme 18: Highly diastereoselective synthesis of pyrrolidine-dipeptoids via a MAO-N/MCR-procedure.
Scheme 19: MAO-N/MCR-approach towards the hepatitis C drug telaprevir.
Scheme 20: Enantioselective MAO-U-3CR procedure starting from chiral pyrroline 64.
Scheme 21: Synthesis of γ-lactams via an UDC-sequence.
Scheme 22: Utilizing bifunctional groups to provide bicyclic γ-lactam-ketopiperazines.
Scheme 23: The Ugi reaction provided both γ- as δ-lactams depending on which inputs were used.
Scheme 24: The sequential Ugi/RCM with olefinic substrates provided bicyclic lactams.
Scheme 25: a) The structural and dipole similarities of the triazole unit with the amide bond. b) The copper-c...
Scheme 26: The Ugi/Click sequence provided triazole based peptidomimetics.
Scheme 27: The Ugi/Click reaction as described by Nanajdenko.
Scheme 28: The Ugi/Click-approach by Pramitha and Bahulayan.
Scheme 29: The Ugi/Click-combination by Niu et al.
Scheme 30: Triazole linked peptidomimetics obtained from two separate MCRs and a sequential Click reaction.
Scheme 31: Copper-free synthesis of triazoles via two MCRs in one-pot.
Scheme 32: The sequential Ugi/Paal–Knorr reaction to afford pyrazoles.
Scheme 33: An intramolecular Paal–Knorr condensation provided under basic conditions pyrazolones.
Scheme 34: Similar cyclization performed under acidic conditions provided pyrazolones without the trifluoroace...
Scheme 35: The Ugi-4CR towards 2,4-disubstituted thiazoles.
Scheme 36: Solid phase approach towards thiazoles.
Scheme 37: Reaction mechanism of formation of thiazole peptidomimetics containing an additional β-lactam moiet...
Scheme 38: The synthesis of the trisubstituted thiazoles could be either performed via an Ugi reaction with pr...
Scheme 39: Performing the Ugi reaction with DMB-protected isocyanide gave access to either oxazoles or thiazol...
Scheme 40: Ugi/cyclization-approach towards 2,5-disubstituted thiazoles. The Ugi reaction was performed with d...
Scheme 41: Further derivatization of the thiazole scaffold.
Scheme 42: Three-step procedure towards the natural product bacillamide C.
Scheme 43: Ugi-4CR to oxazoles reported by Zhu and co-workers.
Scheme 44: Ugi-based synthesis of oxazole-containing peptidomimetics.
Scheme 45: TMNS3 based Ugi reaction for peptidomimics containing a tetrazole.
Scheme 46: Catalytic cycle of the enantioselective Passerini reaction towards tetrazole-based peptidomimetics.
Scheme 47: Tetrazole-based peptidomimetics via an Ugi reaction and a subsequent sigmatropic rearrangement.
Scheme 48: Resin-bound Ugi-approach towards tetrazole-based peptidomimetics.
Scheme 49: Ugi/cyclization approach towards γ/δ/ε-lactam tetrazoles.
Scheme 50: Ugi-3CR to pipecolic acid-based peptidomimetics.
Scheme 51: Staudinger–Aza-Wittig/Ugi-approach towards pipecolic acid peptidomimetics.
Figure 1: The three structural isomers of diketopiperazines. The 2,5-DKP isomer is most common.
Scheme 52: UDC-approach to obtain 2,5-DKPs, either using Armstrong’s isocyanide or via ethylglyoxalate.
Scheme 53: a) Ugi reaction in water gave either 2,5-DKP structures or spiro compounds. b) The Ugi reaction in ...
Scheme 54: Solid-phase approach towards diketopiperazines.
Scheme 55: UDAC-approach towards DKPs.
Scheme 56: The intermediate amide is activated as leaving group by acid and microwave assisted organic synthes...
Scheme 57: UDC-procedure towards active oxytocin inhibitors.
Scheme 58: An improved stereoselective MCR-approach towards the oxytocin inhibitor.
Scheme 59: The less common Ugi reaction towards DKPs, involving a Sn2-substitution.
Figure 2: Spatial similarities between a natural β-turn conformation and a DKP based β-turn mimetic [158].
Scheme 60: Ugi-based syntheses of bicyclic DKPs. The amine component is derived from a coupling between (R)-N-...
Scheme 61: Ugi-based synthesis of β-turn and γ-turn mimetics.
Figure 3: Isocyanide substituted 3,4-dihydropyridin-2-ones, dihydropyridines and the Freidinger lactams. Bio-...
Scheme 62: The mechanism of the 4-CR towards 3,4-dihydropyridine-2-ones 212.
Scheme 63: a) Multiple MCR-approach to provide DHP-peptidomimetic in two-steps. b) A one-pot 6-CR providing th...
Scheme 64: The MCR–alkylation–MCR procedure to obtain either tetrapeptoids or depsipeptides.
Scheme 65: U-3CR/cyclization employing semicarbazone as imine component gave triazine based peptidomimetics.
Scheme 66: 4CR towards triazinane-diones.
Scheme 67: The MCR–alkylation–IMCR-sequence described by our group towards triazinane dione-based peptidomimet...
Scheme 68: Ugi-4CR approaches followed by a cyclization to thiomorpholin-ones (a) and pyrrolidines (b).
Scheme 69: UDC-approach for benzodiazepinones.
Scheme 70: Ugi/Mitsunobu sequence to BDPs.
Scheme 71: A UDAC-approach to BDPs with convertible isocyanides. The corresponding amide is cleaved by microwa...
Scheme 72: microwave assisted post condensation Ugi reaction.
Scheme 73: Benzodiazepinones synthesized via the post-condensation Ugi/ Staudinger–Aza-Wittig cyclization.
Scheme 74: Two Ugi/cyclization approaches utilizing chiral carboxylic acids. Reaction (a) provided the product...
Scheme 75: The mechanism of the Gewald-3CR includes three base-catalysed steps involving first a Knoevnagel–Co...
Scheme 76: Two structural 1,4-thienodiazepine-2,5-dione isomers by U-4CR/cyclization.
Scheme 77: Tetrazole-based diazepinones by UDC-procedure.
Scheme 78: Tetrazole-based BDPs via a sequential Ugi/hydrolysis/coupling.
Scheme 79: MCR synthesis of three different tricyclic BPDs.
Scheme 80: Two similar approaches both involving an Ugi reaction and a Mitsunobu cyclization.
Scheme 81: Mitsunobu–Ugi-approach towards dihydro-1,4-benzoxazepines.
Scheme 82: Ugi reaction towards hetero-aryl fused 5-oxo-1,4-oxazepines.
Scheme 83: a) Ugi/RCM-approach towards nine-membered peptidomimetics b) Sequential peptide-coupling, deprotect...
Scheme 84: Ugi-based synthesis towards cyclic RGD-pentapeptides.
Scheme 85: Ugi/MCR-approach towards 12–15 membered macrocycles.
Scheme 86: Stereoselective Ugi/RCM approach towards 16-membered macrocycles.
Scheme 87: Passerini/RCM-sequence to 22-membered macrocycles.
Scheme 88: UDAC-approach towards 12–18-membered depsipeptides.
Figure 4: Enopeptin A with its more active derivative ADEP-4.
Scheme 89: a) The Joullié–Ugi-approach towards ADEP-4 derivatives b) Ugi-approach for the α,α-dimethylated der...
Scheme 90: Ugi–Click-strategy for 15-membered macrocyclic glyco-peptidomimetics.
Scheme 91: Ugi/Click combinations provided macrocycles containing both a triazole and an oxazole moiety.
Scheme 92: a) A solution-phase procedure towards macrocycles. b) Alternative solid-phase synthesis as was repo...
Scheme 93: Ugi/cyclization towards cyclophane based macrocycles.
Scheme 94: PADAM-strategy towards eurystatin A.
Scheme 95: PADAM-approach for cyclotheanamide.
Scheme 96: A triple MCR-approach affording RGD-pentapeptoids.
Scheme 97: Ugi-MiBs-approach towards peptoid macrocycles.
Scheme 98: Passerini-based MiB approaches towards macrocycles 345 and 346.
Scheme 99: Macrocyclic peptide formation by the use of amphoteric aziridine-based aldehydes.
Beilstein J. Org. Chem. 2014, 10, 425–431, doi:10.3762/bjoc.10.39
Beilstein J. Org. Chem. 2013, 9, 2834–2840, doi:10.3762/bjoc.9.318
Graphical Abstract
Scheme 1: Synthesis of sulfonamide 3, N-alkylation of 3 in organic solution and of CD-complex (3β) in aqueous...
Figure 1: 2D NMR ROESY spectrum of the complex of 3 with β-CD in D2O, displaying the interaction of the tosyl...
Scheme 2: Cyclization of L-(+)-lysine monohydrochloride to give racemate 8.
Figure 2: Oscillatory rheological measurements of an equimolar mixture of 6 and 8 at 50 °C. Illustrated is th...
Beilstein J. Org. Chem. 2013, 9, 2821–2833, doi:10.3762/bjoc.9.317
Graphical Abstract
Figure 1: Unique structural features of (−)-isosteviol.
Figure 2: Triphenylene ketal based on (−)-isosteviol.
Figure 3: Structural features of triptycene derivatives.
Scheme 1: Functionalization of triphenylene ketal 2a.
Figure 4: Hexaammoniumtriptycene hexachloride 4 and 15-oxo-derivatives 5a–c of (–)-isosteviol.
Scheme 2: Quinoxalines based on diketone 5b.
Scheme 3: Condensation of 5b with hexaammoniumtriptycene hexachloride.
Figure 5: Molecular modelling structures (Spartan ’08 V1.0.0) of (a) all-syn-8 and (b) anti,anti,syn-8.
Scheme 4: Synthesis of nitrobenzylic ester derivatives 10 and 11, starting from (−)-isosteviol 1.
Scheme 5: Condensation of the nitrobenzyl esters 10 and 11 with hexaammoniumtriptycene hexachloride 4.
Scheme 6: Hydrogenolysis to tricarboxylic acid all-syn-16.
Scheme 7: Alkylation of all-syn-16 renders terminal alkene all-syn-17.
Figure 6: (a) Top view on the molecular structure of all-syn-17 with the terminal alkene fragments labelled i...
Scheme 8: Alkylation of (−)-isosteviol diketone 9 with 5-bromo-1-pentene.
Scheme 9: Direct synthesis of alkylated triptycene 17 by condensation of 18 with hexaammoniumtriptycene hexac...
Scheme 10: Olefin metathesis of all-syn-17.
Figure 7: Extracts of the 13C NMR spectra of starting material and product.
Figure 8: Molecular modelling structure (MacroModel 9.3.5) of collapsed 19, (a) top view; (b) side view.
Figure 9: Screening of aromatic analytes with affinity materials 3, 7, 8, 17 and 19.
Figure 10: Primary data of anti,anti,syn-8 and a [3 + 2] cage compound (increasing pseudocumene concentrations...
Figure 11: Screening of protic analytes with affinity materials 3, 8, 14 and 15.
Beilstein J. Org. Chem. 2013, 9, 2715–2750, doi:10.3762/bjoc.9.308
Graphical Abstract
Scheme 1: Exemplary 1,3-dipolar cycloaddition of phenylacetylene with phenyl azide [6].
Scheme 2: CuAAC reaction of benzyl azide with (prop-2-yn-1-yloxy)benzene [12].
Scheme 3: Bioconjugation reaction of capsid-bound azide groups with alkynyl-functionalized dye molecules (cow...
Figure 1: Tris(triazolylmethyl)amine ligands for CuAAC applications in bioorganic chemistry: TBTA = tris[(1-b...
Figure 2: Derivatives of 2,2’-bipyridine and 1,10-phenanthroline, commonly used ligands in CuAAC reactions un...
Scheme 4: CuAAC reaction with copper(II) precursor salt and rate-accelerating monodentate phosphoramidite lig...
Scheme 5: Synthesis of 1-(adamant-1-yl)-1H-1,2,3-triazol-4-ylcarbonyl-Phe-Gly-OH by solid-supported Click cat...
Scheme 6: CuAAC reaction with re-usable copper(I)-tren catalyst [129].
Scheme 7: CuAAC test reaction with chlorido[tris(1-benzyl-1H-1,2,3-triazol-4-yl)methanol-κ3N3]copper(I) and a...
Scheme 8: CuAAC model reaction with [Cu2(μ-TBTA-κ4N2,N3,N3’,N3’’)2][BF4]2 [131].
Scheme 9: Application of a (2-aminoarenethiolato)copper(I) complex as homogeneous catalyst for the CuAAC test...
Scheme 10: Application of [CuBr(PPh3)3] as homogeneous catalyst for the CuAAC test reaction of benzyl azide wi...
Figure 3: Phosphinite and phosphonite copper(I) complexes presented by Díez-González [144].
Scheme 11: Effect of additives on the CuAAC test reaction with [(SIMes)CuCl] [149].
Scheme 12: Initiation of the catalytic cycle by formation of the copper acetylide intermediate from [(ICy)2Cu]...
Scheme 13: Early mechanistic proposal by Sharpless [12,42].
Scheme 14: Chemoselective synthesis of a 5-iodo-1,4-disubstituted 1,2,3-triazole [156].
Scheme 15: Mechanistic proposals for the copper-catalyzed azide–iodoalkyne cycloaddition [156].
Scheme 16: 1,3-Dipolar cycloaddition of 3-hexyne catalyzed by [(SIMes)CuBr] [146].
Scheme 17: Mechanistic picture for the cycloaddition of internal alkynes catalyzed by NHC-copper(I) complexes ...
Scheme 18: Catalytic cycle of the CuAAC reaction on the basis of the proposed mechanistic scheme by Fokin and ...
Figure 4: Schematic representation of the single crystal X-ray structures of copper(I) acetylide complexes [Cu...
Figure 5: Acetylide-bridged dicopper complexes with tris(heteroarylmethyl)amine ligand(s) as key intermediate...
Scheme 19: Off-cycle equilibrium between unreactive polymeric copper(I) acetylide species (right) and reactive...
Figure 6: Categories of tris(heteroarylmethyl)amine ligands regarding their binding ability to copper(I) ions ...
Scheme 20: Mechanistic scheme for ligand-accelerated catalysis with tripodal tris(heteroarylmethyl)amine ligan...
Scheme 21: Synthesis of supposed intermediates in the CuAAC’s catalytic cycle [164,187].
Figure 7: Tetranuclear copper acetylide complexes as reported by Weiss (left) [176] and Tasker (middle) [185] and model...
Figure 8: Gibbs free energy diagram for the computed mechanistic pathway of the CuAAC reaction starting from ...
Figure 9: Energy diagram by Ahlquist and Fokin [125].
Scheme 22: Mechanistic proposal for the CuAAC reaction based on DFT calculations by Fokin [125] and our group [186] ([Cu...
Figure 10: ORTEP plot [202,203] of the X-ray powder diffraction crystal structure of (phenylethynyl)copper(I) [(PhC≡CCu)...
Scheme 23: Synthesis of [(PhC≡CCu)2]n as co-product in the Glaser coupling of phenylacetylene in the presence ...
Scheme 24: Mechanistic explanation for the isotopic enrichment in the product triazolide in the presence of th...
Scheme 25: Homogeneous CuAAC catalysis with a bistriazolylidene dicopper complex (0.5 mol %) and comparison wi...
Beilstein J. Org. Chem. 2013, 9, 2660–2668, doi:10.3762/bjoc.9.301
Graphical Abstract
Scheme 1: Key steps from the synthesis of 6-fluoro-D-olivose (6) from D-glucose (1).
Scheme 2: De novo asymmetric syntheses of 6-deoxy-6-fluorohexoses [13].
Scheme 3: Fluorobutenoate building block 14, and related species 16 and 19 from the literature [14-16].
Scheme 4: Fluorobutenoate building blocks 25 and 26 prepared from crotonic acid.
Figure 1: Side product 27 isolated from attempted fluorination.
Figure 2: The ligand panel used in the asymmetric dihydroxylation studies. The bold oxygen shows the point of...
Scheme 5: Typical AD procedure; see Table 1 for outcomes.
Scheme 6: Conversion of enantiomerically-enriched diols to dibenzoates for HPLC analysis.
Figure 3: Diisopropyl L-tartrate (30) used as a chiral modifier for NMR determination of ee.
Figure 4: Partial 19F{1H} NMR spectra (376 MHz, L-(+)-DIPT/CDCl3, 300 K) spectra of (a) racemate 28c, (b) dio...
Figure 5: Partial 19F{1H} NMR (400 MHz, L-(+)-DIPT/CDCl3, 300 K) spectra of 28b and 28a using optimised condi...
Scheme 7: Applying cyclic sulfate methodology to gain access to anti-diastereoisomers (transformations were d...
Scheme 8: Protecting and chain extending the educts of asymmetric dihydroxylation.
Beilstein J. Org. Chem. 2013, 9, 2328–2335, doi:10.3762/bjoc.9.267
Graphical Abstract
Figure 1: Structures of cyclopamine and exo-cyclopamine.
Scheme 1: Synthesis of 25-epi-exo-cyclopamine 5, bis-exo-cyclopamine 6, and derivatives 8 and 9. Reaction con...
Scheme 2: Synthesis of 20-demethyl-bis-exo-cyclopamine 19 and F-nor-20,25-bis-demethyl-exo-cyclopamine 23. Re...
Figure 2: IC50 values of Shh inhibition by compounds 5, 6 and 23 in a Gli1-reporter gene assay. Data were obt...
Beilstein J. Org. Chem. 2013, 9, 2265–2319, doi:10.3762/bjoc.9.265
Graphical Abstract
Scheme 1: Scaled industrial processes for the synthesis of simple pyridines.
Scheme 2: Synthesis of nicotinic acid from 2-methyl-5-ethylpyridine (1.11).
Scheme 3: Synthesis of 3-picoline and nicotinic acid.
Scheme 4: Synthesis of 3-picoline from 2-methylglutarodinitrile 1.19.
Scheme 5: Picoline-based synthesis of clarinex (no yields reported).
Scheme 6: Mode of action of proton-pump inhibitors and structures of the API’s.
Scheme 7: Hantzsch-like route towards the pyridine rings in common proton pump inhibitors.
Figure 1: Structures of rosiglitazone (1.40) and pioglitazone (1.41).
Scheme 8: Synthesis of rosiglitazone.
Scheme 9: Syntheses of 2-pyridones.
Scheme 10: Synthesis and mechanism of 2-pyrone from malic acid.
Scheme 11: Polymer-assisted synthesis of rosiglitazone.
Scheme 12: Synthesis of pioglitazone.
Scheme 13: Meerwein arylation reaction towards pioglitazone.
Scheme 14: Route towards pioglitazone utilising tyrosine.
Scheme 15: Route towards pioglitazone via Darzens ester formation.
Scheme 16: Syntheses of the thiazolidinedione moiety.
Scheme 17: Synthesis of etoricoxib utilising Negishi and Stille cross-coupling reactions.
Scheme 18: Synthesis of etoricoxib via vinamidinium condensation.
Figure 2: Structures of nalidixic acid, levofloxacin and moxifloxacin.
Scheme 19: Synthesis of moxifloxacin.
Scheme 20: Synthesis of (S,S)-2,8-diazabicyclo[4.3.0]nonane 1.105.
Scheme 21: Synthesis of levofloxacin.
Scheme 22: Alternative approach to the levofloxacin core 1.125.
Figure 3: Structures of nifedipine, amlodipine and clevidipine.
Scheme 23: Mg3N2-mediated synthesis of nifedipine.
Scheme 24: Synthesis of rac-amlodipine as besylate salt.
Scheme 25: Aza Diels–Alder approach towards amlodipine.
Scheme 26: Routes towards clevidipine.
Figure 4: Examples of piperidine containing drugs.
Figure 5: Discovery of tiagabine based on early leads.
Scheme 27: Synthetic sequences to tiagabine.
Figure 6: Structures of solifenacin (2.57) and muscarine (2.58).
Scheme 28: Enantioselective synthesis of solifenacin.
Figure 7: Structures of DPP-4 inhibitors of the gliptin-type.
Scheme 29: Formation of inactive diketopiperazines from cis-rotameric precursors.
Figure 8: Co-crystal structure of carmegliptin bound in the human DPP-4 active site (PDB 3kwf).
Scheme 30: Improved route to carmegliptin.
Figure 9: Structures of lamivudine and zidovudine.
Scheme 31: Typical routes accessing uracil, thymine and cytosine.
Scheme 32: Coupling between pyrimidones and riboses via the Vorbrüggen nucleosidation.
Scheme 33: Synthesis of lamivudine.
Scheme 34: Synthesis of raltegravir.
Scheme 35: Mechanistic studies on the formation of 3.22.
Figure 10: Structures of selected pyrimidine containing drugs.
Scheme 36: General preparation of pyrimidines and dihydropyrimidones.
Scheme 37: Synthesis of imatinib.
Scheme 38: Flow synthesis of imatinib.
Scheme 39: Syntheses of erlotinib.
Scheme 40: Synthesis of erlotinib proceeding via Dimroth rearrangement.
Scheme 41: Synthesis of lapatinib.
Scheme 42: Synthesis of rosuvastatin.
Scheme 43: Alternative preparation of the key aldehyde towards rosuvastatin.
Figure 11: Structure comparison between nicotinic acetylcholine receptor agonists.
Scheme 44: Syntheses of varenicline and its key building block 4.5.
Scheme 45: Synthetic access to eszopiclone and brimonidine via quinoxaline intermediates.
Figure 12: Bortezomib bound in an active site of the yeast 20S proteasome ([114], pdb 2F16).
Scheme 46: Asymmetric synthesis of bortezomib.
Figure 13: Structures of some prominent piperazine containing drugs.
Figure 14: Structural comparison between the core of aplaviroc (4.35) and a type-1 β-turn (4.36).
Scheme 47: Examplary synthesis of an aplaviroc analogue via the Ugi-MCR.
Scheme 48: Syntheses of azelastine (5.1).
Figure 15: Structures of captopril, enalapril and cilazapril.
Scheme 49: Synthesis of cilazapril.
Figure 16: Structures of lamotrigine, ceftriaxone and azapropazone.
Scheme 50: Synthesis of lamotrigine.
Scheme 51: Alternative synthesis of lamotrigine (no yields reported).
Figure 17: Structural comparison between imiquimod and the related adenosine nucleoside.
Scheme 52: Conventional synthesis of imiquimod (no yields reported).
Scheme 53: Synthesis of imiquimod.
Scheme 54: Synthesis of imiquimod via tetrazole formation (not all yields reported).
Figure 18: Structures of various anti HIV-medications.
Scheme 55: Synthesis of abacavir.
Figure 19: Structures of diazepam compared to modern replacements.
Scheme 56: Synthesis of ocinaplon.
Scheme 57: Access to zaleplon and indiplon.
Scheme 58: Different routes towards the required N-methylpyrazole 6.65 of sildenafil.
Scheme 59: Polymer-supported reagents in the synthesis of key aminopyrazole 6.72.
Scheme 60: Early synthetic route to sildenafil.
Scheme 61: Convergent preparations of sildenafil.
Figure 20: Comparison of the structures of sildenafil, tadalafil and vardenafil.
Scheme 62: Short route to imidazotriazinones.
Scheme 63: Alternative route towards vardenafils core imidazotriazinone (6.95).
Scheme 64: Bayer’s approach to the vardenafil core.
Scheme 65: Large scale synthesis of vardenafil.
Scheme 66: Mode of action of temozolomide (6.105) as methylating agent.
Scheme 67: Different routes to temozolomide.
Scheme 68: Safer route towards temozolomide.
Figure 21: Some unreported heterocyclic scaffolds in top market drugs.
Beilstein J. Org. Chem. 2013, 9, 1977–2001, doi:10.3762/bjoc.9.234
Graphical Abstract
Scheme 1: Amine radical cations’ mode of reactivity.
Scheme 2: Reductive quenching of photoexcited Ru complexes by Et3N.
Scheme 3: Photoredox aza-Henry reaction.
Scheme 4: Formation of iminium ions using BrCCl3 as stoichiometric oxidant.
Scheme 5: Oxidative functionalization of N-aryltetrahydroisoquinolines using Eosin Y.
Scheme 6: Synthetic and mechanistic studies of Eosin Y-catalyzed aza-Henry reaction.
Scheme 7: Oxidative functionalization of N-aryltetrahydroisoquinolines using RB and GO.
Scheme 8: Merging Ru-based photoredox catalysis and Lewis base catalysis for the Mannich reaction.
Scheme 9: Merging Au-based photoredox catalysis and Lewis base catalysis for the Mannich reaction.
Scheme 10: Merging Ru-based photoredox catalysis and Cu-catalyzed alkynylation reaction.
Scheme 11: Merging Ru-based photoredox catalysis and NHC catalysis.
Scheme 12: 1,3-Dipolar cycloaddition of photogenically formed azomethine ylides.
Scheme 13: Plausible mechanism for photoredox 1,3-dipolar cycloaddition.
Scheme 14: Photoredox-catalyzed cascade reaction for the synthesis of fused isoxazolidines.
Scheme 15: Plausible mechanism for the photoredox-catalyzed cascade reaction.
Scheme 16: Photoredox-catalyzed α-arylation of glycine derivatives.
Scheme 17: Photoredox-catalyzed α-arylation of amides.
Scheme 18: Intramolecular interception of iminium ions by sulfonamides.
Scheme 19: Intramolecular interception of iminium ions by alcohols and sulfonamides.
Scheme 20: Intermolecular interception of iminium ions by phosphites.
Scheme 21: Photoredox-catalyzed oxidative phosphonylation by Eosin Y.
Scheme 22: Conjugated addition of α-amino radicals to Michael acceptors.
Scheme 23: Conjugated addition of α-amino radicals to Michael acceptors assisted by a Brønsted acid.
Scheme 24: Conjugated addition of α-amino radicals derived from anilines to Michael acceptors.
Scheme 25: Oxygen switch between two pathways involving α-amino radicals.
Scheme 26: Interception of α-amino radicals by azodicarboxylates.
Scheme 27: α-Arylation of amines.
Scheme 28: Plausible mechanism for α-arylation of amines.
Scheme 29: Photoinduced C–C bond cleavage of tertiary amines.
Scheme 30: Photoredox cleavage of C–C bonds of 1,2-diamines.
Scheme 31: Proposed mechanism photoredox cleavage of C–C bonds.
Scheme 32: Intermolecular [3 + 2] annulation of cyclopropylamines with olefins.
Scheme 33: Proposed mechanism for intermolecular [3 + 2] annulation.
Scheme 34: Photoinduced clevage of N–N bonds of aromatic hydrazines and hydrazides.
Beilstein J. Org. Chem. 2013, 9, 1630–1636, doi:10.3762/bjoc.9.186
Graphical Abstract
Scheme 1: General scheme for anodic cyclization reactions.
Scheme 2: Anodic cyclization competition study.
Scheme 3: Kolbe electrolysis reactions.
Scheme 4: Oxidative coupling between a carboxylic acid and electron-rich olefin.
Scheme 5: Predicted relative rates of single-electron oxidation based on resonance stabilization of the resul...
Figure 1: Radical cation stabilization by an o-methoxy substituent.